Anti-KIR Antibodies Modulate NK Cell Cytotoxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating autoimmune and inflammatory disorders often rely on immunosuppressive medications that can have severe side effects, and there is a need for more effective ways to modulate NK cell activity to address the role of pro-inflammatory T cells in these conditions.
Innovation Solution
The use of anti-KIR2DL1, 2, and/or 3 antibodies to block or neutralize the inhibitory receptors on NK cells, potentiating their cytotoxic activity against pro-inflammatory T cells, thereby reducing their numbers and mitigating inflammatory or autoimmune disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immunosuppressive medications are used to treat autoimmune and inflammatory disorders, then the activity of pro-inflammatory T cells is reduced, but severe side effects occur
Solution Approach 1:
The patent applies local quality by directing the immunomodulatory effect specifically to NK cells expressing KIR2DL1, KIR2DL2, or KIR2DL3 receptors. The antibody treatment selectively enhances cytotoxic activity only in this specific NK cell subset, rather than broadly suppressing the entire immune system. This localized approach reduces off-target effects on other immune cells and tissues, thereby minimizing severe side effects while maintaining treatment effectiveness against pro-inflammatory T cells.
Solution Approach 2:
The patent uses an antibody as an intermediary substance that binds to KIR2DL1, KIR2DL2, or KIR2DL3 receptors on NK cells. This intermediary blocks the inhibitory signaling pathway, thereby potentiating NK cell cytotoxic activity indirectly. Rather than directly suppressing T cells with immunosuppressants, the antibody mediates the effect by modulating NK cell function, which then leads to reduced T cell activity through enhanced NK cell-mediated cytotoxicity.
2Quantity of substance
If NK cell activity is potentiated to eliminate pro-inflammatory T cells, then the number of pro-inflammatory T cells is reduced, but auto-reactivity-related toxicity may occur
Solution Approach 1:
The patent applies local quality by specifically targeting NK cells that express KIR2DL1, KIR2DL2, or KIR2DL3 receptors. This selective modulation ensures that only specific NK cell subsets with the appropriate receptor profile are activated. The localized enhancement of cytotoxic activity in these specific NK cell populations reduces the risk of widespread auto-reactivity while effectively eliminating pro-inflammatory T cells that express the corresponding ligands.
Solution Approach 2:
The patent employs feedback mechanisms where the antibody treatment potentiates NK cell cytotoxic activity in a controlled manner. The enhanced NK cell activity leads to reduced numbers of pro-inflammatory T cells, which in turn reduces the inflammatory stimulus that would otherwise drive further NK cell activation. This negative feedback loop helps prevent excessive auto-reactivity while maintaining sufficient cytotoxic activity to eliminate pathogenic T cells.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively reduces the number of pro-inflammatory T cells involved in inflammatory or autoimmune disorders without inducing auto-reactivity-related toxicity, offering a potential for improved treatment outcomes with reduced side effects.
Implementation Method 1
administration to an individual having an inflammatory or autoimmune disorder, an amount of a compound that inhibits a KIR2DL1, 2, and/or 3 polypeptide
Data Source
Figure 1A
Figure 1B
Figure 2
AI summary
This invention relates to compounds that inhibit KIR2DL1, 2 and/or 3 polypeptide comprising compounds (e.g., anti-KIR2DL1, 2,-and/or 3 antibodies) that neutralize NK cell inhibitory receptors and methods of using such compounds and compositions containing in the treatment and prevention of inflammatory or autoimmune disorders.